Clinical trials: Androgens
Prostate Cancer, Metastatic Prostate Cancer
The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients
Prostate cancer is the second most common cancer among men. Many patients experience a significantly reduced quality of life due to either the cancer itself or the side effects of treatment.
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer (Post Prostatectomy), Prostate Cancer Patients Treated by Radiotherapy
- Trial name
- ZMoveMent-1 (NCT07126860)
- Testing
- Structured combined resistance and aerobic training, Standard of Care
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Androgen Deficiency, Depressive Symptoms
Physical Exercise for Men With Andropause
The aim of this study is to analyze the impact of physical exercise through a protocol of concurrent training in the psychological, physical, hormonal and sexual aspects in middle aged men with androgen deficiency in the aging…
- Conditions
- Androgen Deficiency, Depressive Symptoms, Stress, Psychological, Abdominal Obesity
- Trial name
- DAEM (NCT03150225)
- Testing
- Concurrent training, Eurycoma longifolia
- Where
- Brazil
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Laboratório de Pesquisa em Lazer e Atividade Física
Prostate Cancer
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled.
- Trial name
- NCT00100243
- Testing
- Plenaxis
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- PRAECIS Pharmaceuticals Inc.
PCOS
Androgen Responses to hCG and Ovarian Morphology in PCOS
Rationale and Hypothesis We have previously reported that theca cells (TC) responses to hCG in women with PCOS represent a spectrum where some exhibit exaggerated increases of 17OHP while in others 17OHP responses resemble those…
- Trial name
- NCT03489668
- Testing
- MetFORMIN 500 Mg Oral Tablet
- Where
- Poland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Poznan University of Medical Sciences
Prostate Cancer, Androgen Deprivation Therapy
Feasibility and Safety of Physical Exercise in Men With Prostate Cancer
Prostate cancer (PCa) is among the most widespread in the male population and represents 19% of all cancers diagnosed from the age of fifty, in Italy.
- Conditions
- Prostate Cancer, Androgen Deprivation Therapy, Radiotherapy
- Trial name
- PCa_Ex (NCT04500080)
- Testing
- PE Intervention
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Prostate Adenocarcinoma
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy.
- Trial name
- NCT03860961
- Testing
- Survivorship Care Plan, Treatment Plan
- Where
- 79 sites in United States
- Volunteers
- 550 people
- Sponsor
- NRG Oncology
Prostate Cancer
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00006359
- Testing
- LHRH agonist, antiandrogen, radiation therapy
- Where
- 26 sites in United States
- Volunteers
- 63 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone (the phase 1 portion of the study) and…
- Trial name
- ASCLEPIuS (NCT04194554)
- Testing
- Niraparib, Leuprolide, Abiraterone Acetate
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- University of Michigan Rogel Cancer Center
Healthy
Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men
This is a prospective, randomized, double-blinded, two-center trial to evaluate the gonadotropin suppressive activity of transdermal treatment with a combined NES/T gel, or T gel alone, for 28 days.
- Trial name
- NCT02432261
- Testing
- Nestorone® /testosterone gel, Testosterone only gel
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Kimberly Myer
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
This phase I/II trial study evaluates the tolerability and best tolerated dose of the PI3K inhibitor GDC-0941 when given with the chemotherapy cisplatin.
- Conditions
- Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01918306
- Testing
- cisplatin, laboratory biomarker analysis, pharmacological study
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Prostate Cancer
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
- Trial name
- NCT05413421
- Testing
- ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 275 people
- Sponsor
- ORIC Pharmaceuticals
Prostatic Neoplasms
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for…
- Trial name
- ENZARAD (NCT02446444)
- Testing
- Enzalutamide, Conventional NSAA, LHRHA
- Where
- 69 sites in United States, Australia and 7 more
- Volunteers
- 802 people
- Sponsor
- University of Sydney
Castration Resistant Metastatic Prostate Cancer
Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
Asymptomatic men with progressive metastatic Castration-resistant prostate cancer (CRPC) post- treatment with abiraterone acetate (pre-chemotherapy for metastatic disease) will be treated on a randomized, multi-Institutional open…
- Trial name
- Transformer (NCT02286921)
- Testing
- Testosterone cypionate, Enzalutamide, Testosterone Enanthate
- Where
- 17 sites in United States
- Volunteers
- 222 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
This study addresses the global topic of treatment optimization, i.e. achieving similar benefit while reducing the duration of treatment, hence hoping to decrease the burden of side-effects, improve quality-of life and reduce…
- Trial name
- NCT05974774
- Testing
- iMAB, cMAB
- Where
- 9 sites in Denmark, France and 1 more
- Volunteers
- 1,600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
The goal of this clinical research study is to find out if a therapy using docetaxel chemotherapy with hormonal therapy taken before your scheduled surgery is beneficial to treatment of prostate cancer.
- Trial name
- NCT01076335
- Testing
- Neoadjuvant Hormonal Therapy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Response
Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients
There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging.
- Trial name
- APPE (NCT00870025)
- Testing
- human chorionic gonadotropin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- IVI Madrid
Prostate Cancer
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression
- Trial name
- NCT00179738
- Testing
- CC5013
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Prostate Cancer
Maintaining Bone Strength in Men With Prostate Cancer
The purpose of this study is to see if giving zoledronic acid three times a year is as effective as five times a year, in increasing bone strength in men with prostate cancer.
- Trial name
- NCT00391950
- Testing
- Zoledronic acid
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Novartis
Castration-Resistant Prostate Cancer (CRPC)
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
- Trial name
- NCT01534052
- Testing
- Enzalutamide
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells.
- Trial name
- NCT00002855
- Testing
- Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.